HELICOVAXOR

Development of an oral Helicobacter Pylori vaccine

 Coordinatore SIGMOID PHARMA LIMITED 

 Organization address address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY
city: DUBLIN
postcode: 9

contact info
Titolo: Dr.
Nome: Rosa
Cognome: Monica
Email: send email
Telefono: 35317007454

 Nazionalità Coordinatore Ireland [IE]
 Totale costo 1˙809˙000 €
 EC contributo 1˙303˙000 €
 Programma FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs
 Code Call FP7-SME-2012
 Funding Scheme BSG-SME
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-10-01   -   2014-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    SIGMOID PHARMA LIMITED

 Organization address address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY
city: DUBLIN
postcode: 9

contact info
Titolo: Dr.
Nome: Rosa
Cognome: Monica
Email: send email
Telefono: 35317007454

IE (DUBLIN) coordinator 1˙169˙500.00
2    TELORMEDIX SA

 Organization address address: Via della Posta 10
city: Bioggio
postcode: 6934

contact info
Titolo: Dr.
Nome: Alcide
Cognome: Barberis
Email: send email
Telefono: +41 91 610 7000

CH (Bioggio) participant 108˙500.00
3    GOTOVAX AB

 Organization address address: KORVETTGATAN 1D
city: VASTRA FROLUNDA
postcode: 42674

contact info
Titolo: Dr.
Nome: Jan
Cognome: Holmgren
Email: send email
Telefono: +46 3 17866200

SE (VASTRA FROLUNDA) participant 25˙000.00
4    ALLIED AUTOMATION LIMITED

 Organization address address: JAMESTOWN ROAD
city: DUBLIN
postcode: 11

contact info
Titolo: Mr.
Nome: Dermot
Cognome: O'brien
Email: send email
Telefono: +353 1 834 3905

IE (DUBLIN) participant 0.00
5    ALMAC DIAGNOSTICS LIMITED

 Organization address address: SEAGOE INDUSTRIAL ESTATE 20
city: CRAIGAVON
postcode: BT63 5QD

contact info
Titolo: Dr.
Nome: Gareth
Cognome: Maguire
Email: send email
Telefono: +44 28 3833 2200
Fax: +44 2838332299

UK (CRAIGAVON) participant 0.00
6    CORDEN PHARMA SWITZERLAND LLC

 Organization address address: EICHENWEG 1
city: LIESTAL
postcode: 4410

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Nsenda
Email: send email
Telefono: +41 61 906 59 59

CH (LIESTAL) participant 0.00
7    DIAMOND BIOPHARM LIMITED

 Organization address address: "GEMINI HOUSE, EAST WING 4"
city: HARLOW
postcode: CM19 5TJ

contact info
Titolo: Mr.
Nome: Paul
Cognome: Cronin
Email: send email
Telefono: +44 1 279 441616

UK (HARLOW) participant 0.00
8    GOETEBORGS UNIVERSITET

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Dr.
Nome: Ellen
Cognome: Rydberg
Email: send email
Telefono: +46 31 7866470

SE (GOETEBORG) participant 0.00
9    MEDITOX S.R.O

 Organization address address: POD ZAMKEM 279
city: KONAROVICE
postcode: 28125

contact info
Titolo: Dr.
Nome: Martin
Cognome: Slais
Email: send email
Telefono: +420 313 129 374 5

CZ (KONAROVICE) participant 0.00
10    PARTICULAR SCIENCES LTD-PSCI

 Organization address address: PARK AVENUE 26 CASTLEKNOCK
city: DUBLIN
postcode: 15

contact info
Titolo: Mr.
Nome: Sean
Cognome: Quilty
Email: send email
Telefono: +353 1 8205395

IE (DUBLIN) participant 0.00
11    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

 Organization address address: College Green -
city: DUBLIN
postcode: 2

contact info
Titolo: Ms.
Nome: Deirdre
Cognome: Savage
Email: send email
Telefono: 35318961942
Fax: 35317071633

IE (DUBLIN) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

infection    orally    efficacy    regulatory    oral    adjuvants    antigens    pylori    safe    powerful    human    vaccine    helicobacter    clinical    safety    antibodies   

 Obiettivo del progetto (Objective)

'Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.

Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine: - Powerful, safe and multivalent antigens - Powerful, safe and multi-acting adjuvants - Powerful, modular and flexible oral vaccine delivery system

All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely:

- Antigens – produce antibodies against a number of key H pylori bacterial components - Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies - Delivery – formulate antigens and adjuvants together and target the stomach and intestine

This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.

This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies.

If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection.'

Introduzione (Teaser)

A European consortium is developing a novel, orally delivered vaccine against Helicobacter pylori. Using encapsulating technology the vaccine will be administered orally, thereby directly reaching the site of H. pylori infection.

Altri progetti dello stesso programma (FP7-SME)

FACIT-SME (2010)

Facilitate IT-providing SMEs by Operation-related Models and Methods

Read More  

LIMOWOOD (2013)

Advanced wood plastic composite material for the production of bath furniture resistant to moisture and free of coatings

Read More  

NEFELE (2011)

Nano- Electrospun Filter for Efficient Liberation & Encapsulation of acticides for water treatment in transportation applications

Read More